There are currently two RET inhibitors on the market in China, platinib and seputinib.

At present, both drugs have not been included in medical insurance, but both drugs have drug donation policies. Platinib’s charity drug donation program is buy 1 and get 1 free in the first phase, buy 4 and get 6 free in the second phase, and buy 4 and get 6 free in the third phase.

Buy 2 and get 10 free, then buy 2 and get 10 free.

The free drug plan for Seputinib is buy 2 and get 2 free in the first phase, and buy 4 and get 4 free cycles in the second phase.

Platinib is 300,000 in the first year, 120,000 in the second year, and 120,000 in the third year.

Septinib costs 390,000 per year.

In addition, Huimin Insurance (urban insurance) discounts can also reduce the financial burden of patients to a certain extent. Seputinib has not yet joined the city Huimin Insurance shortly after it was launched, while Platinib, which has been on the market for nearly 2 years, currently covers more than 100 patients.

Most of the urban welfare insurances stipulate that even sick people can be insured (most commercial insurances will restrict the insurance for sick people). This provision has greatly reduced the financial burden of cancer patients.

Take Shandong’s “Rizhao Warm Heart Insurance” and “Jihui Bao”’s pre-existing condition compensation ratio as 60%, and Zhejiang’s “Huimin Bao” also pays around 50%.

In areas covered by the Huimin Insurance, platinib is more "people-friendly" and the annual treatment cost is further reduced.

For specific compensation cities and policies, you can check the "Life Watch" public account under the Life Oasis Foundation.